Alembic Pharmaceuticals Ltd Share Price Today - Alembic Pharmaceuticals Ltd Stock Price Live NSE/BSE

Alembic Pharmaceuticals Ltd

NSE: APLLTD BSE: 533573

₹677.30

(3.33%)

Tue, 31 Mar 2026, 08:35 am

MTF 5xInvest in Alembic Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap133.08B

PE Ratio21.17

Dividend1.62

Health Technology

Pharmaceuticals: Major

24.5K

Alembic Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
13009.53
Net Profit
582.01
P/B
3.52
Sector P/E
31.93
P/E
31.31
EV/EBITDA
18.25
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
11.63
ROCE
13.08
Debt/Equity
0.18
EPS (TTM)
33.75
Dividend Yield
1.66
Book Value
270.62
Interest Cover
9.98

Analysis

all

Pros

Dividends paid are well covered by earnings (6.3x coverage).
Dividends after 3 years are expected to be well covered by earnings (4.4x coverage).
Alembic Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
Cash flow for Alembic Pharmaceuticals is expected to increase by more than 50% in 2 years time.
Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.

Cons

Dividend payments have increased, but Alembic Pharmaceuticals only paid a dividend in the past 8 years.
Whilst dividend payments have been stable, Alembic Pharmaceuticals has been paying a dividend for less than 10 years.
Alembic Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
Alembic Pharmaceuticals's earnings are expected to grow by 0.5% yearly, however this is not considered high growth (20% yearly).
Alembic Pharmaceuticals's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	69.74	69.74	69.67	69.67	69.61
FII	4.24	4.05	3.96	3.94	4.17
DII	16.17	16.30	16.46	16.43	16.06
Public	9.85	9.92	9.90	9.96	10.16
Government	0	0	0	0	0

Technical Analysis

RSI

38.45

MACD

-22.70

50 DMA

739.70

200 DMA

883.67

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	992.78	870.33	790.77	747.88	668.32	625.43	502.98
Fibonacci	870.33	823.56	794.66	747.88	701.11	672.21	625.43
Camarilla	744.87	733.65	722.42	747.88	699.98	688.75	677.53

Pivots Level: Classic

+244.90

992.78

+122.45

870.33

+42.88

790.77

747.88

Pivot Point

LTP: 663.25

-79.57

668.32

-122.45

625.43

-244.90

502.98

Moving Average

SMAEMA

Period

Value

10-EMA
675.92
20-EMA
691.56
30-EMA
707.67
50-EMA
736.11
100-EMA
788.70
200-EMA
846.84

Announcement Date	Purpose	Action	Ex Date
05 Feb 2026	board-meetings	Quarterly Results, Nine Months Results
04 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
29 Jun 2025	dividend	Final Dividend - Rs. - 11	29 Jul 2025
11 Jun 2025	agm
06 May 2025	dividend	₹11.00 Dividend /Share	29 Jul 2025
21 Jun 2024	agm
15 Jun 2024	dividend	Final Dividend - Rs. - 11	15 Jul 2024
09 May 2024	dividend	₹11.00 Dividend /Share	15 Jul 2024
28 Jun 2023	dividend	Final Dividend - Rs. - 8	28 Jul 2023
05 Jun 2023	agm

Alembic Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Lupin Ltd

Divis Laboratories Ltd

Alembic Pharmaceuticals Ltd About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2010

Headquarters

CEO

Chirayu R Amin

Employees

Contact

Website

http://www.alembicpharmaceuticals.com/

apl.investors@alembic.co.in

Phone

91-0265-2280550

Location

Alembic Road, , Vadodara, Gujarat, 390003

Year	History
2021	Alembic receives USFDA tentative approval for Selexipag Tablets. Alembic Pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules. Alembic Pharma gets USFDA nod for cancer treatment drug. Alembic Pharmaceuticals has subscribed to partnership interest in ABCD Technologies LLP.
2022	Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules. Alembic Pharma gets USFDA nod for Entacapone tablets. Alembic Pharmaceuticals gets US FDA nod for antibiotic drug.
2023	Alembic has a cumulative total of 182 ANDA approvals from USFDA.
2024	Alembic Pharmaceuticals has received USFDA approval for generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy. Alembic Pharmaceuticals has received USFDA approval for generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia. Alembic Pharmaceuticals has received USFDA approval for the abbreviated new drug application (ANDA) for Ivosidenib tablets of strength 250 mg
2025	Alembic Pharmaceuticals Ltd. announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Alembic Pharmaceuticals Ltd has received final approval from the USFDA for its generic version of Sumatriptan Injection. Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Carbamazepine extended-release tablets. Alembic Pharmaceuticals Ltd. has received USFDA Final Approval for Ticagrelor Tablets, 60 mg. Alembic Pharmaceuticals Ltd. announces USFDA Final Approval for Bosutinib Tablets, 100 mg and 500 mg.

Client Name	Order Side	QTY	Avg Price	Date
VIRAMYA PACKLIGHT LLP	Sell	1000000	595	23 Mar 2017
SHRENO LIMITED	Buy	1000000	595	23 Mar 2017

Alembic Pharmaceuticals Ltd News

Alembic Pharma Gets US FDA Approval for Paroxetine

Alembic Pharmaceuticals receives US FDA final approval for Paroxetine Extended-Release 12.5 mg tablets, similar to Paxil CR, expanding its US ANDA portfolio to 235 approvals.

27 Mar 2026

companies

Alembic Pharma Gets US FDA Approval for Paroxetine

Alembic Pharmaceuticals receives US FDA final approval for Paroxetine Extended-Release 12.5 mg tablets, similar to Paxil CR, expanding its US ANDA portfolio to 235 approvals.

27 Mar 2026

companies

Alembic Pharma Schedules Investor Meet with Nomura

Alembic Pharmaceuticals has announced a one-on-one investor meeting with Nomura Holdings scheduled for March 24, 2026, to be conducted via video conferencing.

20 Mar 2026

companies

Alembic Pharma Creates New Subsidiary In Thailand

Alembic Pharmaceuticals establishes new subsidiary in Thailand to expand its international operations and strengthen presence in Southeast Asian pharmaceutical market.

09 Mar 2026

stocks

Alembic Pharmaceuticals Reports First US Pivya Sale

Alembic Pharmaceuticals announces first prescription sale of Pivya (pivmecillinam) tablets in US, marking entry into branded pharmaceuticals market through subsidiary Alembic Therapeutics LLC.

06 Mar 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800